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Non-malignant effusionsAbstract Back ground: Pleural effusion remains a diagnostic challenge. A number of tumor mark-
ers might facilitate the identiﬁcation of patients with malignancies.
Objective: To assess the value of Dikkopf-1 concentrations in both serum and pleural ﬂuid in the
differentiation between malignant and non malignant pleural effusions.
Methods: 47 patients with pleural effusions were enrolled in the study. They were classiﬁed into
two groups: group I: 24 patients with malignant effusions, group II: 23 patients with non malignant
effusions. Thoracentesis with biochemical, cytological and bacteriological examination of pleural
ﬂuid and determination of Dikkopf-1 level in serum and pleural ﬂuid were done.
Results: Serum and pleural levels of DKK-1 were signiﬁcantly higher in the malignant group
compared with the non-malignant group. At cut off point 3091 pg/ml serum DKK-1 shows
100% sensitivity and 91.3% speciﬁcity while at cut off point 4607 pg/ml pleural DKK-1 levels
showed 100% sensitivity and 100% speciﬁcity. In the non malignant group, serum and pleural levels
of DKK-1 were signiﬁcantly higher in TB patients compared to pneumonia and liver cirrhosis.
Conclusions: Malignant effusions are associated with elevated serum and pleural DKK-1 level
but it cannot be used as sure marker for the diagnosis of malignancy since it rises in many other
conditions.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).rculosis.
Table 1 The diagnosis of the studied patients.
Diagnosis No. %
Group I (n= 24)
Mesothelioma 12 50.0
Bronchogenic carcinoma 6 25.0
Metastasis 6 25.0
Group II (n= 23)
TB eﬀusion 7 30.4
Para-pneumonia eﬀusion 9 39.1
Liver cirrhosis 7 30.4
Table 2 Comparison between the studied groups as regards
serum and pleural Dikkopf-1.
Group I (n= 24) Group II (n= 23) P
Serum Dikkopf-1 (pg/ml)
Mean± SD 5580.33 ± 995.38 2389.35 ± 866.49 <0.001*
Pleural Dikkopf-1 (pg/ml)
Mean± SD 7453.3 ± 1271.9 2516.57 ± 952.23 <0.001*
* Means highly signiﬁcance.
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Pleural effusion is an excess ﬂuid accumulating between the
two pleural layers [1]. The etiological diagnosis of pleural effu-
sion is frequently a problem in clinical practice, especially in
the differentiation between malignant and benign pleural
effusions [2]. Even with the use of invasive procedures, such
as thoracoscopy and cytological examination, 10–20% of
patients remain without diagnosis [3].
In an attempt to improve the identiﬁcation of malignant
cases, various studies have reported the usefulness of biological
tumor markers [4]. Tumor markers that are currently available
such as carcinoembryonic antigen, cytokeratin19 fragment,
neuro-speciﬁc enolase and progastrin-releasing peptide, are
neither satisfactory for diagnosis at an early stage nor for mon-
itoring the disease because of their relatively low sensitivity
and speciﬁcity [5].
Dikkopf-1 is a member of Dikkopf family of secreted pro-
teins that is known as a negative regulator of the Wnt signaling
pathway, which plays an important role in the development
and regulation of proliferation, differentiation, survival, apop-
tosis, and cell motility [6].
The change in Dikkopf-1 expression has been reported in
several types of cancers including multiple myeloma and can-
cers of the colon, breast, prostate as well as the lung [7].
Aim of the work
The aim of this study was to assess the value of Dikkopf-1 con-
centrations in both serum and pleural ﬂuid for the purpose of
differentiation between malignant and non malignant pleural
effusions.
Patients and methods
The study was conducted in the Chest Department, Menouﬁa
University Hospital, Egypt, during the period from October
2013 to September 2014. The study included 47 patients
diagnosed as pleural effusion, which were classiﬁed into two
groups:
 Group I: included 24 patients with malignant pleural
effusions.
 Group II: included 23 patients with benign pleural
effusions.
All patients were subjected to history taking, general and
local examination, and radiological evaluation, Thoracentesis
and pleural ﬂuid analysis for biochemical, bacteriological
and cytological examinations, laboratory investigations
including CBC, ESR, measurement of serum and pleural levels
of DKK-1 using human DKK-1 ELISA Kit, QumikineTM assay,
Biotechnology, USA [8].
Statistical analysis
Data were collected, tabulated, and statistically analyzed using
SPSS, version 20. Sensitivity, speciﬁcity, positive predictive
value (PPV), negative predictive value (NPV), and accuracy
were calculated. More than two populations were analyzedby ANOVA and Post Hoc test (LSD). Correlations between
two quantitative variables were assessed using Pearson coefﬁ-
cient. P value was considered signiﬁcant if 60.05 and highly
signiﬁcant if 60.01.
Results
There was no signiﬁcantly statistical difference between both
groups regarding age and sex. In group I, 12 patients (50%)
were suffering from mesothelioma 6 patients (25%) had bron-
chogenic carcinoma and 6 patients (25%) presented with
metastasis. In group II, 9 patients (39.1%) were suffering from
para-pneumonic effusions, 7 patients (30.4%) had liver cirrho-
sis and 7 patients (30.4%) had tuberculous pleural effusions
(Table 1). In this study, serum and pleural levels of DKK-1
were higher in the malignant group compared to the non
malignant group (P< 0.001) (Table 2) and that pleural
DKK-1 levels were signiﬁcantly higher than serum levels in
the same group (P< 0.001) (Table 3). Serum and pleural
levels of DKK-1 were signiﬁcantly higher in bronchogenic car-
cinoma compared to mesothelioma and metastasis (Fig. 1).
Results also showed with a cut-off point 3091 pg/ml of serum
DKK-1, sensitivity will be 100%, speciﬁcity 91.3%, PPV
92.3% and NPV 100% while using a cut-off point of
4607 pg/ml of pleural DKK-1, the sensitivity, speciﬁcity,
PPV and NPV will be 100% (Table 4). In the non malignant
group, serum and pleural levels of DKK-1 were signiﬁcantly
higher in TB patients compared to pneumonia and liver cirrho-
sis (Fig. 2).
Discussion
The etiological diagnosis of pleural effusion is frequently a
problem in clinical practice in the identiﬁcation of malignant
cases. Various studies have reported the usefulness of biologi-
cal tumor markers. The aim of this work was to study the
Table 3 Comparison between serum and pleural Dikkopf-1
level in each of the studied groups.
Serum Dikkopf-1
(pg/ml)
Pleural Dikkopf-1
(pg/ml)
P
Group I (n= 24)
Mean ± SD 5580.33 ± 995.38 7453.3 ± 1271.9 <0.001*
Group II (n= 23)
Mean ± SD 2389.35 ± 866.49 2516.57 ± 952.23 0.493
* Means highly signiﬁcance.
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for malignant pleural effusion by ELISA technique.
In the present study the levels of both serum and pleural
ﬂuid Dikkopf-1 were highly signiﬁcantly increased in group I
patients with malignant effusions than in group II patients
with non malignant effusions (P< 0.001).
These results agreed with those of Yamabuki et al. [9] and
Sheng et al. [6] who detected increased DKK-1 levels in serum
of lung cancer patients by ELISA in comparison with benign
lung tumors and healthy subjects suggesting its potential role
in the development or progression of lung cancer. DKK-1
expression could promote dissemination of lung tumor by
stimulating cell invasion. This was based on the ﬁnding that
induction of exogenous expression of DKK-1 enhanced the
cellular migration/invasive activity of mammalian cells [9].0
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Figure 1 The level of serum and pleural Dikkop
Table 4 Utility of Dikkopf-1 in the diagnosis of malignancy.
Group2 Group1
Serum Dikkopf-1 63091 pg/ml 21 0
>3091 pg/ml 2 24
Pleural Dikkopf-1 64607 pg/ml 23 0
>4607 pg/ml 0 24In the present study, the pleural Dikkopf-1 level was highly
signiﬁcantly higher than serum level in group I (P< 0.001).
On the other hand, there was no signiﬁcant difference between
serum and pleural levels of Dikkopf-1 in group II (p= 0.493)
Studies describing DKK-1 levels in the pleural ﬂuid in lung
cancer are scanty but its presence in malignant cell lines can
be a possible explanation of the local increase in malignant
effusions. In the present study the sensitivity of both serum
and pleural ﬂuid was 100% and the speciﬁcity in the pleural
ﬂuid was 100% while in the serum it was 91.30%.
Both serum and pleural Dikkopf-1 levels were highly signif-
icantly increased in patients with bronchogenic carcinoma
(6389.17 ± 623.84 pg/ml, 8625.83 ± 1038.34 pg/ml respec-
tively) compared with their levels in patients with mesothe-
lioma (5184.50 ± 539.29 pg/ml, 6908.67 ± 771.50 pg/ml
respectively), while, there was a non-signiﬁcant difference in
pleural and serum Dikkopf-1 between patients with mesothe-
lioma and metastasis or between patients with bronchogenic
carcinoma and patients with metastasis. The presence of pleu-
ral ﬁbrosis and decreased shedding in cases with mesothelioma
might explain the scarcity of the marker in the pleural ﬂuid.
Meloti et al. [10] showed that DKK-1 was used to induce
apoptosis of malignant mesothelioma cells by antagonizing
Wnt signaling independently of b-catenin [11]. On the other
hands, the inhibitory effect of DKK-1 would maintain
stemness and inappropriate persistent DKK-1 and BMI-1
expression would ultimately lead to malignant transformation,Pleural Dikkopf-1
f-1 in different types of malignant effusions.
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Figure 2 Comparison of serum and pleural levels of DKK-1 in different types of non malignant effusions.
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state [10] explaining the increased level of serum and pleural
Dikkopf-1 in patients with mesothelioma but not more than
patients with bronchogenic carcinoma.
Yamabuki et al. [9] and Sheng et al. [6] detected increased
DKK-1 levels in lung cancer patients with progression of the
disease stage and the occurrence of distant metastasis specially
in the bones. However the patients included in this study were
not proved to have bone affection .The increase in serum
DKK-1 could be due to circulatory factors stimulating
DKK-1 production as CD8 and tumor necrosis factor (TNF)
and the increase in pleural DKK-1 could be due to the same
factors in addition to local production by malignant cells.
In non malignant effusions, the present study showed that
there was a signiﬁcant increase in the level of serum
Dikkopf-1 in TB patients (3267.0 ± 964.59 pg/mL) compared
to patients with pneumonia and a highly signiﬁcant increase
compared to those with liver cirrhosis (2243.56 ± 329.36 pg/ml,
1699.14 ± 437.66 pg/ml) respectively. TB patients also had
signiﬁcantly higher levels of Dikkopf-1 in pleural ﬂuid
(3290.57 ± 830.50 pg/ml) than in patients with cirrhosis and
those with pneumonia (1742.43 ± 290.74 pg/ml, 2516.67
± 929.56 pg/ml) respectively. The study of Dhruv et al. [12]
showed that CD8 T cells and TNF are believed to participate
in the immune response to mycobacterium tuberculosis infec-
tion in humans. The study of Yeremenko et al. [13] showed
that DKK-1 production is strongly upregulated by TNF which
correlates DKK-1 levels with these pro-inﬂammatory cytoki-
nes levels. This explains the increase of serum and pleural
DKK-1 in TB more than in pneumonia, where neutrophils
can increase the level of DKK-1 but not as high as in TB.
Conclusion
Malignant effusions were strongly associated with elevated
serum and pleural DKK-1 level and determination of its levelcould be beneﬁcial in early diagnosis and risk stratiﬁcation of
the disease. However, it cannot be considered as a sure diag-
nostic marker since it can be expressed in multiple conditions,
whether inﬂammatory, degenerative or others.
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